This review highlights the need for a better understanding of the mechanisms underlying diastolic dysfunction, particularly chamber stiffness, to identify novel therapeutic targets for heart failure with preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
Incomplete mechanistic understanding of diastolic dysfunction cautions against premature HFpEF targeting; leaves open identification of regulators and therapies.
Abnormalities of diastolic function are common to virtually all forms of cardiac failure. However, their underlying mechanisms, precise role in the generation and phenotypic expression of heart failure, and value as specific therapeutic targets remain poorly understood. A growing proportion of heart failure patients, particularly among the elderly, have apparently preserved systolic function, and this is fueling interest for better understanding and treating diastolic abnormalities. Much of the attention in clinical and experimental studies has focused on relaxation and filling abnormalities of the heart, whereas chamber stiffness has been less well studied, particularly in humans. Nonetheless, new insights from basic and clinical research are helping define the regulators of diastolic dysfunction and illuminate novel targets for treatment. This review puts these developments into perspective with the major aim of highlighting current knowledge gaps and controversies.
No takes yet. Share an insight, caveat, or question.
Kass et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: